

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	ı	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/698,124		10/31/2003	Kenneth T. Heruth	P-9986.00	P-9986.00 8969	
27581	7590	10/20/2006		EXAM	EXAMINER	
MEDTRO!				MACNEILL, ELIZABETH		
710 MEDTRONIC PARK MINNEAPOLIS, MN 55432-9924				ART UNIT	PAPER NUMBER	
				3767	.	
				DATE MAILED: 10/20/2000	DATE MAILED: 10/20/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

SX
$\times u$
D

	Application No.	Applicant(s)					
	10/698,124	HERUTH, KENNETH T.					
Office Action Summary	Examiner	Art Unit					
	Elizabeth R. MacNeill	3767					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status							
 1) Responsive to communication(s) filed on 31 Octobriance 2a) This action is FINAL. 2b) This 3) Since this application is in condition for allower closed in accordance with the practice under Exercise 	action is non-final. nce except for formal matters, pro						
Disposition of Claims							
4) Claim(s) 1-25 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) Claim(s) is/are allowed. 6) Claim(s) 1-25 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or election requirement.							
Application Papers							
 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on 31 October 2003 is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. 							
Priority under 35 U.S.C. § 119							
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 							
Attachment(s) Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO/SB/08) Paper Ne(s)/Mail Date 10/31/2003	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	ite					

Application/Control Number: 10/698,124 Page 2

Art Unit: 3767

DETAILED ACTION

Claim Rejections - 35 USC § 101

1. 35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

2. Claims 1-8 are rejected under 35 U.S.C. 101 because the claimed invention is not supported by either a specific and substantial asserted utility or a well established utility.

No utility is indicated in claims 1-8. The steps of "measuring" and then "estimating" do not produce a concrete, reproducible result. A further step, which possesses a specific, well established and substantial utility must be claimed.

Claims 1-8 are also rejected under 35 U.S.C. 112, first paragraph. Specifically, since the claimed invention is not supported by either a specific and substantial asserted utility or a well established utility for the reasons set forth above, one skilled in the art clearly would not know how to use the claimed invention.

Claim Rejections - 35 USC § 103

- 3. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 4. Claims are rejected under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over STULTZ (US 2002/0156462).

Application/Control Number: 10/698,124

Art Unit: 3767

Regarding claims 1 and 9, Stultz teaches a method for sensing food intake comprising measuring a parameter, estimating a relationship, and delivering a programmed amount of one or more medications as a function of the sensed physiological parameter (P0012). Stultz does not specifically teach that the sensed parameters are related to food intake, however it is well known that glucose level is inherently tied to food intake.

Regarding claims 2-8,16-18, 24 and 25 Stultz teaches the measurements of the "muscle tone, heart rate, respiration rate, blood oxygen saturation, physical activity, temperature, glucose level, and the like" (P0012)

Regarding claims 10,12, and 19, Stultz teaches "The sensor may sense the glucose level present in body fluids, and in response to sensing a glucose level that is out of range of predetermined acceptable levels, cause the pump to take appropriate corrective action by delivering an appropriate medication(s)" (P0029). It is well known in the art that insulin and glucagon are known medications that are appropriate for the treatment of glucose levels (See also MAULT (US 2003/0208113, P0038)

Regarding claim 11, Stultz again teaches the estimation of a physical activity level (P0012) and the delivery of an appropriate medication. It is well known in the art that glucagon is a known medication (See also MAULT (US 2003/0208113, P0038)

Regarding claim 13, Stultz teaches a system comprising a sensor (18), a processor (34), and a drug delivery system (30) (Fig 3)

Regarding claim 14, the drug delivery system comprises a reservoir (30) and a pump (33)

Application/Control Number: 10/698,124

Art Unit: 3767

÷.,

Regarding claim 15, the system is implanted (Fig 4)

Regarding claim 20, the system comprises a first reservoir (30a), a first pump (35a), a second reservoir (30b) and a second pump (35b). It is well known in the art that insulin and glucagon are known medications that are appropriate for the treatment of a patient and could be stored in either reservoir (See also MAULT (US 2003/0208113, P0038)

Regarding claim 21, the processor generates first and second signals for the control of the separate pumps (Abstract, P0036)

Regarding claim 22, there is a memory coupled to the processor (P0036, P0030)

Regarding claim 23, Stultz teaches a computer readable medium which causes a processor to estimate a quantity of food consumed by a patient and deliver a therapy (P0029)

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Elizabeth R. MacNeill whose telephone number is (571)-272-9970. The examiner can normally be reached on 7:00-3:30pm M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Kevin Sirmons can be reached on (571)272-4965. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/698,124 Page 5

Art Unit: 3767

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only.

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

ERM

KEVIN C. SIRMONS SUPERVISORY PATENT EXAMINER

Musi C. Sumons

٠,